• Existing Student?   Click Here to Login
IfappAcademy.org
  • WELCOME TOIFAPP ACADEMY
    • WELCOME
    • STRATEGIC ALLIANCE KING’S COLLEGE LONDON
    • VALUE OF CERTIFICATION
    • VALUE OF MEDICAL AFFAIRS
    • HOT TOPICS OF MEDICAL AFFAIRS
  • WHY MEDICALAFFAIRS
    • CORE CAPABILITIES
    • COMPETENCIES
    • WHATS NEW IN MEDICAL AFFAIRS
  • PROSPECTIVESTUDENTS
    • REQUIREMENTS
    • BENEFITS
    • CERTIFICATION, ACCREDITATION, & CREDENTIALING
    • 2021 PROGRAM INFORMATION & APPLICATION
  • PROGRAM
    • PROGRAM DETAILS
    • TIMELINES
    • LEARNING OUTCOMES
  • ABOUT US
    • NEWS FROM IFAPP ACADEMY
    • BOARD OF OFFICERS
    • ADVISORY COUNCIL
    • FACULTY
  • CONTACT US
  • Search
  • Menu Menu
  • Facebook
  • LinkedIn
  • Youtube
  • WELCOME TOIFAPP ACADEMY
    • WELCOME
    • STRATEGIC ALLIANCE KING’S COLLEGE LONDON
    • VALUE OF CERTIFICATION
    • VALUE OF MEDICAL AFFAIRS
    • HOT TOPICS OF MEDICAL AFFAIRS
  • WHY MEDICALAFFAIRS
    • CORE CAPABILITIES
    • COMPETENCIES
    • WHATS NEW IN MEDICAL AFFAIRS
  • PROSPECTIVESTUDENTS
    • REQUIREMENTS
    • BENEFITS
    • CERTIFICATION, ACCREDITATION, & CREDENTIALING
    • 2021 PROGRAM INFORMATION & APPLICATION
  • PROGRAM
    • PROGRAM DETAILS
    • TIMELINES
    • LEARNING OUTCOMES
  • ABOUT US
    • NEWS FROM IFAPP ACADEMY
    • BOARD OF OFFICERS
    • ADVISORY COUNCIL
    • FACULTY
  • CONTACT US
You are here: Home1 / Clinical Trial Guidance for use during COVID-19 Pandemic2 / Hot Topics in Medical Affairs3 / Clinical Trial Guidance for use during COVID-19 Pandemic

Clinical Trial Guidance for use during COVID-19 Pandemic

April 1, 2020/in Hot Topics in Medical Affairs /by Amanda Schmitt
Important Clinical Trial Guidance for use during COVID-19 Pandemic

We know that Medical Affairs and Medicines Development Professionals around the world have been working non-stop to develop vaccines, treatments, testing, and medical devices in response to the COVID-19 pandemic. To aide in the distribution of information, we have provided below important clinical trial guidance from different sources for use during this pandemic.

We wish everyone health and safety during this difficult time!


The below document was released by ACRO – Association of Clinical Research Organizations

Considerations to Support Clinical Trial Monitoring Oversight During COVID-19, 13 March 2020

The emerging coronavirus (COVID-19) situation is increasingly impacting clinical trial oversight, particularly on-site monitoring. The Association of Clinical Research Organizations (ACRO) recommends that sponsors, CROs and sites introduce emergency interim measures so that clinical trial monitoring is maintained during this period. These guidelines will ensure that data quality is unaffected, clinical trial sites are supported and that the patients enrolled in clinical trials are kept safe.
The use of centralized monitoring tools and technologies can supplement and support the recommendations outlined below. These practices and tools are already in place and do not require any additional sophisticated analytical tools or dashboards. Care should be taken that any remote monitoring activities implemented are proportionate to the risks identified. Further, they should not place any extra burden on clinical trial sites.

These recommendations should be considered in the following situations:
• When sites have suspended or restricted all visitors (including clinical research associates (CRAs)) from accessing medical facilities, but where patient visits are still occurring
• When local health officials have implemented regional quarantines
• When local CRAs are unable to travel to the sites (for personal health reasons or because of travel restrictions)

Click the following download button to view the entire document: ACRO-Statement-on-Monitoring-Oversight-FINAL-3.13.20Download

The below document was released by the European Medicines Agency (EMA).

Guidance on the Management of Clinical Trials during the COVID 19 (Coronavirus) pandemic Version 1 (20/03/2020)

The European Medicines Agency (EMA), Good Clinical Practice (GCP) Inspectors Working Group, the Clinical Trials Facilitation and Coordination Group (CTFG, a working group of the Heads of Medicines Agency (HMA)), the Clinical Trials Expert Group (CTEG, a working group of the European Commission representing Ethics Committees and National Competent Authorities) and the European Commission (EC) acknowledge the impact of COVID-19 on the health system and broader society, and the impact it may have on clinical trials and trial participants1. Extraordinary measures may need to be implemented and trials adjusted due to e.g. trial participants being in self-isolation/quarantine, limited access to public places (including hospitals) due to the risk of spreading infections, and health care professionals being committed to critical tasks. Therefore, EMA, EC and HMA strongly support the efforts of the GCP Inspectors’ Working Group for developing harmonised EU/EAA-level guidance to mitigate the negative effects of the COVID-19 pandemic on the conduct of clinical trials.

The situation is evolving, and pragmatic actions may be required to deal with the challenges of conducting research, and in ensuring the rights, safety and wellbeing of participants. The points mentioned below are intended to provide guidance for all parties involved in clinical trials during this time.

Due to the urgency, this guidance is issued without prior public consultation. The sponsors should note that due to the rapidly evolving situation further updates to this guidance are possible and likely.

Click the following download button to view the entire document: EMA-guidanceclinicaltrials_covid19_enDownload

The below document was released by the FDA (Federal Drug Administration)

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic

Guidance for Industry, Investigators, and Institutional Review Boards (March 2020)

I. Introduction The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States from threats including emerging infectious diseases, including the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support continuity and response efforts to this pandemic.
FDA is issuing this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.

Given this public health emergency, this guidance is being implemented without prior public comment because the FDA has determined that prior public participation for this guidance is not feasible or appropriate (see section 701(h)(1)(C)(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and 21 CFR 10.115(g)(2)). This guidance document is being implemented immediately, but it remains subject to comment in accordance with the Agency’s good guidance practices.

In general, FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidance means that something is suggested or recommended, but not required.

Click the following download button to view the entire document: FDA-COVID-19_FDA-17Mar2020Download

Tags: clinical trial guidance, clinical trials, coronavirus, COVID-19, IFAPP Academy, Medical Affairs, medical affairs professional, pandemic guidance
Share this entry
  • Share on Facebook
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
You might also like
Here’s why you should join (and follow!) the IFAPP Academy on LinkedIn! - IfappAcademy.org Here’s why you should join (and follow!) the IFAPP Academy on LinkedIn!
Building on the phenomenal accomplishments in an exceptionally challenging year, the IFAPP Academy is poised for expanding its global communications outreach in 2021, as the fountainhead in the realm of education and training in medicines development. To champion this cause, the elite cadre of biopharmaceuticals professionals, convened under the banner of an Editorial Board, will be designated as the IFAPP Academy’s Scientific Advisory Committee, to more pertinently reflect the considerably expanded remit and scope of oversight envisaged for a burgeoning global community of learners. In alignment with the IFAPP Academy and IFAPP governance, the Scientific Advisory Committee, chaired by Pravin Chopra, will drive the strategic communications framework and guidance for engaging key stakeholders. The Committee will oversee the Academy’s growing Value-Added Programs and Services offerings, and direct the Academy’s external scientific exchange platforms aspiring to inform, educate, and engender dialogue on trending topics and advancements in biopharmaceutical medicines development and medical affairs. The ongoing pandemic has fueled the imperative for virtual connectivity and networking amongst patient advocates and biomedical professionals, and the Academy gratefully acknowledges the valued expertise, insights, and leadership of the Scientific Advisory Committee members as we enter a new era of healthcare innovation. Scientific Advisory Committee to spearhead IFAPP Academy’s learning outreach ambitions
What are the benefits of earning a professional certification? - IfappAcademy.org What are the benefits of earning a professional certification?
King's College London: "From Molecules to Medicines" - IfappAcademy.org King’s College London: “From Molecules to Medicines”
Core Competencies of Medical Affairs The IFAPP Academy’s Core Competencies are truly ‘the Core of Medical Affairs’
IFAPP Academy Meeting in Budapest - IfappAcademy.org IFAPP Academy Meeting in Budapest
  • News from IFAPP Academy
  • Hot Topics of Medical Affairs – IFAPP Academy

Newsletter

Archives

IFAPP Academy provides an online, continuing professional development course, Medical Affairs in Medicines Development, resulting in the Professional Certification, Certified Medicines Development (CMD).

 Site Map | Contact Us |Privacy Policy | Cookies
© Copyright - IfappAcademy.org - powered by Enfold WordPress Theme
  • Facebook
  • LinkedIn
  • Youtube
Gustavo Kesselring Appointed New CIOMS Executive Committee Member Representing... Dr. Gustavo Kesselring, IFAPP Academy VP with CIOMS group in Geneva IFAPP Academy at MAPS Global Conference in Miami IFAPP Academy Executive team at MAPS Global Conference in Miami
Scroll to top